Evidence map›Paper›PMID 31606876›Full record

ArticleJournal of neuro-oncology2019

Impact of adjuvant fractionated stereotactic radiotherapy dose on local control of brain metastases.

Hima B Musunuru, Jacob S Witt, Poonam Yadav, David M Francis, Aleksandra Kuczmarska-Haas, Zacariah E Labby, Michael F Bassetti, Steven P Howard, Andrew M Baschnagel

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hima B MusunuruDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
Jacob S WittDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
Poonam YadavDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
David M FrancisDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
Aleksandra Kuczmarska-HaasDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
Zacariah E LabbyDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
Michael F BassettiDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
Steven P HowardDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA.
Andrew M BaschnagelDepartment of Human Oncology, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI, 53792, USA. baschnagel@humonc.wisc.edu.
University of Wisconsin Carbone Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to determine whether a higher biological effective dose (BED) would result in improved local control in patients treated with fractionated stereotactic radiotherapy (FSRT) for their resected brain metastases.

methodsPatients with newly diagnosed brain metastases without previous brain radiotherapy were retrospectively reviewed. Patients underwent surgical resection of at least one brain metastasis and were treated with adjuvant FSRT, delivering 25-36 Gy in 5-6 fractions. Outcomes were computed using Kaplan-Meier survival analysis and univariate analysis.

resultsFifty-four patients with 63 post-operative cavities were included. Median follow-up was 16 months (3-60). Median metastasis size at diagnosis was 2.9 cm (0.6-8.1) and median planning target volume was 19.7 cm

conclusionIn the post-operative setting, high-dose FSRT (BED

Indexed as

AdultAgedAged, 80 and overBrain NeoplasmsChemoradiotherapy, AdjuvantDose Fractionation, RadiationFemaleHumansKaplan-Meier EstimateMaleMiddle AgedRadiosurgeryRetrospective StudiesTreatment OutcomeBrain metastasesFractionated stereotactic radiotherapyRadiation

Identifiers

PMID31606876
OpenAlexW2979764736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.